Anemia management: Development of a rapid-access anemia and intravenous iron service

Risk Management and Healthcare Policy

Volumn 6, Issue , 2013, Pages 13-22

  Radia, Deepti ^a   Momoh, Ibrahim ^b   Dillon, Richard ^a   Francis, Yvonne ^a   Cameron, Laura ^a   Fagg, Toni Lee ^a   Overland, Hannah ^a   Robinson, Susan ^a   Harrison, Claire N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b Bupa Home Healthcare   (United Kingdom)

Author keywords

Ferric carboxymaltose; Hemoglobin; Iron deficiency; Iron dextran; Iron isomaltoside; Iron sucrose

Indexed keywords

ANTIANEMIC AGENT; CYANOCOBALAMIN; ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FOLIC ACID; IRON; IRON DEXTRAN; IRON ISOMALTOSIDE; IRON SACCHARATE; MONOFER; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL PROTOCOL; DIET; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG MEGADOSE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH SERVICE; HOSPITAL SERVICE; HUMAN; INVESTIGATIVE PROCEDURES; IRON THERAPY; NATIONAL HEALTH SERVICE; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; PATIENT SATISFACTION; SINGLE DRUG DOSE; UNITED KINGDOM;

EID: 84881267691     PISSN: None     EISSN: 11791594     Source Type: Journal    
DOI: 10.2147/RMHP.S41818     Document Type: Article

References (18)

1. Komajda M, Anker SD, Charlesworth A, etal. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27(12):1440-1446.
2. Nathavitharana RL, Murray JA, D'Sousa N, Sheehan T, Frampton CM, Baker BW. Anaemia is highly prevalent among unselected internal medicine inpatients and is associated with increased mortality, earlier readmission and more prolonged hospital stay: an observational retrospective cohort study. Intern Med J. 2012;42(6):683-691.
3. Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopath Med Prim Care. 2007;1:14.
4. Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH. Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. J Am Soc Nephrol. 2006;17(12):3497-3502.
5. Barroso F, Allard S, Kahan BC, etal. Prevalence of maternal anaemia and its predictors: a multi-centre study. Eur J Obstet Gynecol Reprod Biol. 2011;159(1):99-105.
6. Goodhand JR, Kamperidis N, Rao A, etal. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(3):513-519.
7. Department of Health. Better blood transfusion: safe and appropriate use of blood. 2007. Available from: http://webarchive.nationalarchives.gov.uk/20120405095111/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_080803.pdf. Accessed November 16, 2011.
8. Department of Health. Tackling hospital waiting: the 18 week patient pathway-an implementation framework and delivery resource pack. 2006. Available from: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4134668. Accessed April 15 2013.
9. Momoh I, Foster K, Meaney L, etal. Use of erythropoietin (EPO) in adult patients prior to elective major orthopaedics surgery to reduce exposure to allogeneic blood transfusion: a pilot study [abstract]. Br J Haematol. 2009;145 Suppl 1:81-82.
10. Momoh I. Anaemia and the nurse-led clinic outside renal care. Br J Card Nurs. 2010;5(9):432-438.
11. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF), 62nd ed. London: Pharmaceutical Press; 2011.
12. Electronic Medicines Compendium. Venofer (iron sucrose)-summary of product characteristics. 2011. Available from: http://www.medicines.org.uk/EMC/medicine/24168/SPC/Venofer+(iron+sucrose). Accessed November 16, 2011.
13. Electronic Medicines Compendium. Cosmofer-summary of product characteristics. 2012. Available from: http://www.medicines.org.uk/EMC/medicine/14139/SPC/CosmoFer. Accessed April 15, 2013.
14. Electronic Medicines Compendium. Ferinject-summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/24167/SPC/Ferinject+ferric+carboxymaltose. 2013. Accessed April 15, 2013.
15. Electronic Medicines Compendium. Monofer 100mg/mL for injection/infusion-summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/23669/SPC/Monofer+100mg+ml+solution+for+ injection+infusion. 2013. Accessed April 15, 2013.
16. Dillon R, Momoh I, Francis Y, Cameron L, Harrison C, Radia D. Comparative efficacy of three forms of parenteral iron. J Blood Trans. 2012;2012:473514.
17. National Health Service Improvement [homepage on the Internet]. Available from: http://www.improvement.nhs.uk/qipp. Accessed November 16, 2011.
18. NHS Institute for Innovation and Improvement. Better care, better value indicators (incorporating opportunity locator). Available from: http://www.productivity.nhs.uk/Indicator/608/For/National/And/25th/Percentile. Accessed November 16, 2011.